SCLEROSTIN

PreclinicalBiologic

MMedical University of Lublin

SCLEROSTIN is one of 6 biologic programs targeting Mastocytosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MastocytosisActive, not recruiting

MastocytosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Mastocytosis

#DrugCompanyPhaseTrials

Plaquenil

Alnylam Pharmaceuticals

Rydapt

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 4

Masitinib

AAB Science

Phase 2

2 5

Cromoglicate

LEO Pharma

Phase 2

1 6

SCLEROSTIN

MMedical University of Lublin

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Mastocytosis

NCT06440148

Clinical

Trials by Indication[1]

Mastocytosis1 trial

Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis

Recruiting·MMedical University of Lublin··NCT06440148·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SCLEROSTIN. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCLEROSTIN compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCLEROSTIN. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Lublin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMedical University of Lublin

SCLEROSTIN

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Mastocytosis1 trial

References

Drug Info

Quick Facts

Related News